Hepatic Resection in Patients with Liver Metastasis from Gastric Cancer

위암의 간전이에 대한 간 절제 수술

  • Jun, Kyong-Hwa (Department of Surgery, St. Vincent's Hospital, The Catholic University of Korea College of Medicine) ;
  • Chin, Hyung-Min (Department of Surgery, St. Vincent's Hospital, The Catholic University of Korea College of Medicine)
  • 전경화 (가톨릭대학교 의과대학 외과학교실) ;
  • 진형민 (가톨릭대학교 의과대학 외과학교실)
  • Received : 2009.03.09
  • Accepted : 2009.03.23
  • Published : 2009.03.31

Abstract

The clinical significance of hepatic resection for gastric metastases is controversial, even though hepatic resection has been widely accepted as a modality for colorectal metastases. Very few patients with gastric hepatic metastases are good candidates for hepatic resection because of multiple bilateral metastases, extrahepatic disease, or advanced cancer progression, such as peritoneal dissemination or extensive lymph node metastases. Therefore, several authors have reported the clinical significance of hepatic resection for gastric metastases in a small number of patients. Considering the present results with previous reports. The number and distribution of tumors in hepatic metastases from gastric cancer was considered based on the present and previous reports. Several authors have reported significantly better survival in patients with metachronous metastasis than in those with synchronous disease. However, metachronous hepatic resection necessitates the dissection of adhesions between the pancreas, liver, and residual stomach to prepare for Pringle's maneuver. Patients with unilobar liver metastasis, and/or metastatic tumors <4 cm in diameter may be good candidates for hepatic resection. Synchronous metastasis is not a contraindication for hepatic resection. Most of the long-term survivors underwent anatomic hepatic resection with a sufficient resection margin. After hepatic resection, the most frequent site of recurrence was the remaining liver, which was associated with a high frequency of mortality within 2 years. A reasonable strategy for improvement in survival would be to prevent recurrence by means of adjuvant chemotherapy and careful follow-up studies.

대장암이나 타 장기 암의 간전이 경우 간 절제는 비교적 좋은 결과를 가지는 치료 방법으로 보고되고 있으나, 위암의 간전이에 대한 치료로 절제 수술의 역할과 생존율에 대한 효과는 연구가 많지 않은 실정이다. 위암의 수술 전 진단 때나 수술 후 추적 검사 중 진단된 간전이의 경우 많은 예에서 다발성 전이, 좌, 우엽에 전이, 간외 전이, 복막 파종이나 다발성 림프절 전이 양상으로 절제 수술의 적응이 되지 못하는 악성 경로를 가지는 경우가 많다. 그러나 몇몇 보고에서는 수술 적응 대상 환자가 적으나 간절제 치료로 좋은 결과를 보고하는 경우도 있어 제한된 간전이 환자에 대한 맞춤 치료의 영역은 있다고 하였다. 위암의 간전이 절제 예에 대한 보고를 종합하여 보면 간전이 병소가 진단되는 시기가 예후에 중요하여 동시성으로 전이가 진단된 경우가 나쁘며, 절제연이 10 mm 이상 유지 될 때 좋은 결과를 보고하였다. 반면 전이 병소의 개수는 생존율 검사에서 통계학적 의미는 없는 것으로 보고 되었다. 또한 충분한 절제연을 확보하면서 해부학적 구역 절제 이상의 수술이 시행된 경우와 이시성 간전이가 좋은 생존율을 보이는 것으로 보고되었다. 또한 간 절제 수술 후 가장 많은 재발 병소는 역시 간으로, 재발 시 대부분 2년 내 사망을 초래하여 절제 후 보조항암화학요법 치료도 중요하다.

Keywords

References

  1. Scheele J, Stangl R, Altendorf-Hofmann A. Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history. Br J Surg 1990;77:1241-1246. https://doi.org/10.1002/bjs.1800771115
  2. Sakamoto Y, Ohyama S, Yamamoto J, Yamada K, Seki M, Ohta K, Kokudo N, Yamaguchi T, Muto T, Makuuchi M. Surgical resection of liver metastases of gastric cancer: An analysis of 17-year experience with 22 patients. Surgery 2003;133:507-511. https://doi.org/10.1067/msy.2003.147
  3. Dhar DK, Kubota A, Yamanoi A. Selective approaches to gastric cancer patients with liver metastases. Digest Liver Dis 2001;33:614.
  4. Roh H, Suh K, Lee H, Yang H, Choe K, Lee K. Outcome of hepatic resection for metastatic gastric cancer. Amer Surg 2005;71:95-99.
  5. Ambiru S, Miyazaki M, Ito H, Nakagawa K, Shimizu H, Yoshidome H, Shimizu Y, Nakajima N. Benefits and limits of hepatic resection for gastric metastases. Am J Surg 2001;181:279-283. https://doi.org/10.1016/S0002-9610(01)00567-0
  6. Sakamoto Y, Sano T, Shimada K, Esaki M, Saka M, Fukagawa T, Katai H, Kosuge T, Sasako M. Favorable indications for hepatectomy in patients with liver metastasis from gastric cancer. J Surg Oncol 2007;95:534-539. https://doi.org/10.1002/jso.20739
  7. Khatri VP, Chee KG, Petrelli NJ. Modern multimodality approach to hepatic colorectal metastases: Solutions and controversies. Surg Oncol 2007;16:71-83. https://doi.org/10.1016/j.suronc.2007.05.001
  8. Makuuchi M, Thai BL, Takayasu K. Preoperative portal embolization to increase safety of major hepatectomy for hilar bile duct carcinoma: a preliminary report. Surgery 1990;107:521-527.
  9. Khatri VP, McGahan J. Non-resection approaches for colorectal liver metastases. Surg Clin North Am 2004;84:587-606. https://doi.org/10.1016/j.suc.2003.12.007
  10. Benoist S, Brouquet A, Penna C. Complete response of colorectal liver metastases after chemotherapy: does it mean cure? J Clin Oncol 2006;24:3939-3945. https://doi.org/10.1200/JCO.2006.05.8727